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Stem cell-based therapies have carried the hopes of researchers, physicians and patients for over 
thirty years, showing great promise in their 
ability to restore damaged and diseased 
organs and tissue. Most stem cell 
therapies rely on adult stem cells called 
mesenchymal stem cells (MSCs), which 
can differentiate into cartilage, bone, 
connective tissue, muscle or adipose (fat) 
tissue. MSCs can be obtained from almost 
any organs or tissues (bone marrow, lung, 
spleen, liver, fat etc.). The MSCs derived 
from fat tissue are called adipose stem 
cells (ASCs) and these can be isolated 
with minimal ethical conflict.
Until recently, bone marrow served as 
the main source of MSCs. However, 
adipose tissue became much more 
attractive as researchers realised that 
ASCs were abundantly available and 
could be easily and repeatedly sampled 
with minimally invasive procedures. 
Furthermore, adipose stem cells have 
demonstrated low immunogenicity (i.e., 
they are unlikely to react with the immune 
system) and some immunosuppressive 
properties which prevent the body from 
rejecting them – making them safe for 
therapeutic use. As a result, ASCs have 
been used in several 
clinical trials to treat 
conditions such 
as diabetes 
mellitus, liver 
disease, 
traumatic 
injuries and 
corneal 
lesions, 
worldwide.
However, further 
research into human 
and mouse ASCs has revealed that they 
are prone to chromosomal instability – 
they may lose or gain chromosomes. 
These kinds of mutations have been 
associated with cancer and, while no 
cancerous transformations of ASCs have 
been observed yet, ASCs have been 
shown to incorporate into tumours and 
promote their growth, raising concerns 
about the true safety of ASC therapies. 
Now, research led by Dr Robert Katona 
of the Biological Research Centre of 
the Hungarian Academy of Sciences’ 
Institute of Genetics has shown that 
ASCs with an abnormal number of 
chromosomes may promote cancer 
development and act as tumour support 
structures, known as stroma.
INVESTIGATING ASC 
BEHAVIOUR IN MICE
In order to get a better understanding 
of ASC behaviour, Dr Katona and his 
team extracted the visceral fat – the deep 
abdominal fat that surrounds organs 
– from mice and cultured the visceral 
adipose stem cells (vASCs) in vitro 
for several months.
The changes were almost immediate 
and cell growth and division slowed 
down, with cell numbers decreasing in 
the first few weeks. Soon after, the cells 
began to deteriorate, becoming enlarged 
and flattened, with most stopping 
growth and proliferation altogether. 
Surprisingly, however, some continued to 
divide and after 50 days, the cell culture 
had grown beyond the initial sample size. 
By now, the cells were showing signs 
of increased DNA content, with most 
cells having four or more copies of 
at least one chromosome, rather than 
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the usual two, causing cells to have even 
up to 163 chromosomes in total, rather 
than the usual 40. This was confirmed 
using flow cytometry – where a liquid 
cell culture is poured down a tube 
and passed through one or more lasers 
to determine the physical and chemical 
properties of the cells – and microscopy. 
In both cases, DNA within the cells was 
stained so that it would fluoresce when 
hit with a laser and become visible 
to the researchers.
This result is significant as multiple DNA 
copies can lead to altered gene expression 
and change the cells’ behaviour.
To see how the cells’ gene expression 
and behaviour had changed, the 
researchers developed an immortalised 
ASC cell line, containing the abnormal 
DNA configuration which they called 
ASC.B6 and compared its activity to 
original vASCs. While the ASC.B6 
cells were still able to differentiate into 
mature cells as normal, transcriptome 
analysis – study of the total sum of 
messenger RNA (an intermediary 
between DNA and proteins) present 
in the cell – showed that 2395 genes 
were being expressed at least twice 
as much or as low as normal.
In particular, genes and gene products 
responsible for cell growth, division 
and movement were overrepresented 
in ASC.B6, showing that these 
cells might be involved in cancer 
development. This was backed by 
increased expression of cancer stem cell 
markers Sca-1, CD29, and Krüppel-like 
factor 4 (Klf4). Interestingly, expression 
of another cancer stem cell marker, 
Nestin, actually decreased.
ASCs CAN PROMOTE TUMOUR  
CELL GROWTH
To demonstrate this, Dr Katona and his 
team co-cultured the 4T1 murine breast 
cancer cell line with vASCs or ASC.B6. 
Both ASC cultures enhanced proliferation 
of 4T1, although ASC.B6 did so far more 
than the vASCs. Surprisingly, most of the 
tumour-promoting growth factors were 
expressed at similar levels in both vASCs 
and ASC.B6. However, expression of one 
tumour-promoting growth factor, insulin-
like growth factor 1 (IGF1), increased 
in ASC.B6 compared to vASCs (IGF1 
production of vASCs was only initiated 
when they started to show increased 
DNA content) and was found in the broth 
surrounding both cultures. Moreover, 
treatment with an IGF1 antibody 
significantly decreased tumour growth, 
suggesting that IGF1 production was 
at least partly responsible for ASC.B6’s 
tumour growth promoting effect.
WHY IGF1?
IGF1 is responsible for promoting 
mammary terminal end bud, ductal and 
gland formation in healthy mammals. 
While it’s mostly produced in the liver, it 
is also expressed in mammary stromal 
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Metaphase chromosome spreads were made from colchicine-blocked vASCs at passage numbers 4 
and 7, and ASC.B6. Chromosomes were DAPI stained and counted using a fluorescent microscope.
Fifty thousand vASCs were plated and cultured in triplicate samples. Cells were passaged when the 
culture reached confluency and the living cell number of vASCs was determined with trypan blue staining 
and counting with BioRad TC10 counter device. The graph shows the average ± SD of living cell numbers 
in three parallel samples. The x-axis indicates days in culture from the initial plating, and the measuring 
points are referred as p1 to p13. A representative of three independent experiments is shown.
The DNA content of vASCs at passage 
numbers 3, 6 and 10 and of ASC.B6 cell line 
was determined by propidium-iodide staining 
and flow cytometric analysis.
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Personal Response
Given your results, would you suggest people 
reconsider the use of therapeutic ASCs and if so, under 
what circumstances?
  Yes, but people should receive ASC therapy only 
if all the safety issues have been addressed by double 
blind, regulated and controlled clinical trials. Any clinically 
unproven procedures should be strongly avoided.
Dr Katona’s work uses a mouse adipose stem cell model 
system to study cancer and cancer stem cell development.
Dr Robert Katona
like a lot of effort, finding effective 
therapeutic targets against tumour 
stroma, such as ASCs, is critical, as their 
secretion of IGF1 can lead to cancer drug 
resistance, minimising the effectiveness 
of treatments and leading to poorer 
patient prognosis.
CAN THE MOUSE MODEL 
BE APPLIED TO PEOPLE? 
Dr Katona believes it can. Mouse models 
are used due to their high similarity with 
humans, (we share 85% of our protein-
coding DNA). As a result, cancerous 
activities observed in mice would most 
likely reflect those in humans. Just as 
in mice ASCs, ageing and deteriorating 
human ASC cultures have had altered 
chromosome numbers. Dr Katona 
expects this would also be the case 
in the body and could be due to higher 
concentrations of reactive oxygen 
species or inflammatory mediators 
which promote chronic inflammation 
in the tumour microenvironment.
While Dr Katona hopes that his mouse 
ASC model could be used for further 
research into the genes responsible 
for cancer development and potential 
treatments targeting tumour stroma, 
his findings could also influence future 
use of therapeutic ASCs.
– increased blood sugar – and metabolic 
syndrome in patients while receptor 
tyrosine kinase inhibitors led to patients 
developing metabolic toxicities.
Currently, researchers are exploring 
alternative anti-IGF1 antibodies, with 
some successfully slowing or even 
inhibiting cancer proliferation in late-
stage cancer patients. While this sounds 
cells. As a result, overexpression of IGF1 
can lead to breast cancer development, 
progression and metastasis. This is 
reflected in Dr Katona’s results where 
he exposed vASCs and ASC.B6 to 4T1 
murine breast cancer cells. 
The tumour-promoting effect of IGF1 
is often heightened when it binds to 
its receptor – IGF1R. This makes it a 
promising target for human breast cancer 
therapies and several researchers have 
already attempted clinical trials that treat 
breast cancer with IGF1R or receptor 
tyrosine kinase inhibitors. Unfortunately, 
these clinical trials were stopped as IGF1R 
antibody therapy caused hyperglycaemia 
By now, the cells were showing signs 
of increased DNA content, with... cells 
having up to 163 chromosomes in total, 
rather than the usual 40.
Cell surface markers of vASCs at passage 3 and ASC.B6 cells were 
detected by flow cytometry and the percentage of positive cells was 
determined. The bars show the mean ± SD from three independent 
experiments, the statistical analysis was t-test with P-values set at: 
*P < 0.05, **P < 0.01.
Functional enrichment analysis done by IPA for the identification of biological 
functions and diseases that were most profoundly represented by the 
differentially expressed genes. Only carcinogenesis associated categories are 
presented, all of which are highly affected. Right-tailed Fisher’s exact test was 
used to calculate a p-value. False discovery rates (FDR) were generated based 
on the Benjamini-Hochberg corrected p-values.
vASCs at passage numbers 3, 6 and 10 and ASC.B6 cell line were stained for SA-βgal activity  
for 16 h and then the blue staining (senescence) was detected with an inverted light microscope.
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